ArticleEmerging infectious diseases2026
Wastewater Respiratory Virus Surveillance in Remote Community, Alaska, USA, 2022-2024.
Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wastewater surveillance (WS) is underused in rural communities. We evaluated WS performance in the remote, subarctic, mostly Indigenous, community of Bethel, Alaska, USA, during October 2022-May 2024. Wastewater was collected >3 times weekly and underwent on-site PCR testing for SARS-CoV-2, respiratory syncytial virus (RSV), and influenza A and B viruses. We compared WS virus detection with local clinical data by using results from 318 wastewater samples and 7,392 clinical tests. We detected SARS-CoV-2 in 265 (83.3%) wastewater samples, influenza A virus in 128 (40.3%), RSV in 78 (24.5%), and influenza B virus in 29 (9.1%). Wastewater signals correlated with clinical results for influenza B virus (Spearman ρ = 0.85), influenza A virus (ρ = 0.62), RSV (ρ = 0.60), and SARS-CoV-2 (ρ = 0.59), providing corroborating data that informed the timing of seasonal respiratory virus immunization campaigns. Our findings show that WS is feasible and useful for disease surveillance in rural Alaska.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.